Literature DB >> 30525101

Expanding the chemotherapeutic potential of an established nucleoside analog with selective targeting of telomerase.

Tawna L Whited1, Derek J Taylor1,2.   

Abstract

The identification of telomerase-mediated telomeric misincorporation of 5-fluoro-2'-deoxyuridine (5-FdU) uncovered a unique approach to telomeric-based therapeutics. Additionally, identification of such a mechanism supports the utility of telomere maintenance mechanisms in guiding therapeutic decisions. Presented here is a unique perspective of 5-FdU and its clinical implications as a telomeric-based therapeutic.

Entities:  

Keywords:  5-fluoro-2ʹ-deoxyuridine; alternative lengthening of telomeres; floxuridine; nucleoside analog; telomerase; telomere

Year:  2018        PMID： 30525101      PMCID： PMC6276856          DOI： 10.1080/23723556.2018.1536844

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Telomere maintenance by telomerase and by recombination can coexist in human cells.

Authors:  M A Cerone; J A Londono-Vallejo; S Bacchetti
Journal:  Hum Mol Genet       Date:  2001-09-01       Impact factor: 6.150

Review 2.  Molecular mechanisms of activity and derepression of alternative lengthening of telomeres.

Authors:  Hilda A Pickett; Roger R Reddel
Journal:  Nat Struct Mol Biol       Date:  2015-11-04       Impact factor: 15.369

Review 3.  A survey of telomerase activity in human cancer.

Authors:  J W Shay; S Bacchetti
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

4.  Administration of a Nucleoside Analog Promotes Cancer Cell Death in a Telomerase-Dependent Manner.

Authors:  Xuehuo Zeng; Wilnelly Hernandez-Sanchez; Mengyuan Xu; Tawna L Whited; Diane Baus; Junran Zhang; Anthony J Berdis; Derek J Taylor
Journal:  Cell Rep       Date:  2018-06-05       Impact factor: 9.423

Review 5.  [The role of alternative lengthening of telomeres mechanisms in carcinogenesis and prospects for using an anti-telomerase drugs in malignant tumors treatment].

Authors:  A A Grach
Journal:  Tsitologiia       Date:  2011

6.  How telomeres solve the end-protection problem.

Authors:  Titia de Lange
Journal:  Science       Date:  2009-11-13       Impact factor: 47.728

Review 7.  5-fluorouracil: mechanisms of action and clinical strategies.

Authors:  Daniel B Longley; D Paul Harkin; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

8.  Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition.

Authors:  Oliver E Bechter; Ying Zou; William Walker; Woodring E Wright; Jerry W Shay
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

9.  Twisted epithelial-to-mesenchymal transition promotes progression of surviving bladder cancer T24 cells with hTERT-dysfunction.

Authors:  Yan Xue; Lei Li; Dong Zhang; Kaijie Wu; Yule Chen; Jin Zeng; Xinyang Wang; Dalin He
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

Review 10.  Telomere and Telomerase Therapeutics in Cancer.

Authors:  Yucheng Xu; Amir Goldkorn
Journal:  Genes (Basel)       Date:  2016-05-26       Impact factor: 4.096
  10 in total
  1 in total

Review 1.  The evolution of nucleosidic analogues: self-assembly of prodrugs into nanoparticles for cancer drug delivery.

Authors:  Milad Baroud; Elise Lepeltier; Sylvain Thepot; Yolla El-Makhour; Olivier Duval
Journal:  Nanoscale Adv       Date:  2021-02-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.